21h
Zacks Investment Research on MSNWhy Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 1.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...
Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...
Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...
Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...
In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...
Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook ...
Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
BIIB) shares lost a similar percentage, Bernstein analysts argued. While the DCF valuation indicates an undervalued stock, Bernstein thinks that BIIB is valued on a near-term growth outlook ...
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results